Roughly one in 10 Americans have diabetes, and 90–95% of those have type 2 diabetes (1). Uncontrolled diabetes can lead to serious complications, including heart disease, vision impairment, and kidney damage (1). Tirzepatide, a once-weekly injectable medication in late-stage development, has shown promise in its ability to treat type 2 diabetes (2–5).

Tirzepatide has not yet been approved by the U.S. Food and Drug Administration (FDA). If approved it is expected to have an indication for the treatment of type 2 diabetes.

Tirzepatide is an injectable dual glucagon-like peptide 1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (6). GIP is considered the dominant insulinotropic hormone when compared with GLP-1 and has demonstrated a stronger role in postprandial insulin secretion (7).

Impressive A1C reductions to ≤5.7% (discussed below) are unique and highlight the potential clinical efficacy of...

You do not currently have access to this content.